Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Single Agent News

Single Agent News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Single Agent. Real-time updates on events, politics, business and more.

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

May 1, 2024
These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication ...
United States Merck Research Laboratories Drug Administration Merck Co Inc European Society For Medical Oncology Statement Of Merck Co Inc
Source: marketscreener.com

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

January 5, 2024
Global Phase 3 studies started for bomedemstat , nemtabrutinib , MK-2870 and MK-5684 Comprehensive clinical development programs being initiated for each investigational candidate Demonstrates...
United States Drug Administration Exchange Commission Merck Co Inc American Society For Hematology Merck Research Laboratories
Source: marketscreener.com

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

January 1, 2024
New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program
United States Prnewswire Johnson Natashab Leighl None Of Janssen Research Development Janssen Research Development Janssen Biotech Inc
Source: telegraphherald.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

September 15, 2023
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial ...
United States Gregory Lubiniecki Merck Research Laboratories European Union European Organisation For Research Merck Co Inc
Source: marketscreener.com

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

July 19, 2023
KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
United States Domenica Lorusso Gursel Aktan European Network For Gynaecological Oncology Trial Foundation Inc Exchange Commission
Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science